Back to Resource Center / Insights / Posted on 06-04-2025
On May 15, 2025, the Departments of Labor, Health and Human Services (HHS), and the Treasury (the Departments) announced they will not enforce the September 2024 regulations implementing the non-quantitative treatment limitation (NQTL) comparative analysis requirement under the Mental Health Parity and Addiction Equity Act (MHPAEA) as required by the Consolidated Appropriations Act, 2021. The required analysis applies to group health plans, including drug coverage.
The Department’s nonenforcement position stems from the January 2025 ERIC lawsuit challenging the 2024 regulations and Executive Order 14219 directing federal agencies review and exercise enforcement discretion for regulations that impose undue burdens on small businesses or significant costs on private parties that do not outweigh the public benefits.
Specifically, the Departments will not enforce the 2024 regulations prior to the final decision in the ERIC lawsuit, plus an additional 18 months. Critically, the Department’s nonenforcement position only applies to the 2024 regulations; it does not extend to the 2013 MHPAEA regulations or eliminate the need to have an NQTL comparative analysis as statutorily required by the CAA, 2021.
The Departments confirm that the 2013 regulations and subregulatory guidance, such as FAQs About Mental Health and Substance Use Disorder Parity Implementation and the Consolidated Appropriations Act, 2021 Part 45, should continue to be referred to for guidance despite the nonenforcement of the 2024 regulations.
Next Steps for Plan Sponsors
Considering the announced nonenforcement policy employers should review their MHPAEA compliance strategy. Employers, as plan sponsors, are responsible for ensuring their plans are compliant with the MHPAEA including the February 2021 CAA requirement to have an NQTL comparative analysis. The 2024 regulations provided specific information about what an NQTL comparative analysis required and even though the 2024 regulations will not be enforced, the requirement to have an NQTL comparative analysis still exists.
The 2024 regulations regarding the requirements of the NQTL comparative analysis will not be enforced for the time being. Employers, as plan sponsors, should continue to monitor the status of the 2024 regulations and watch for additional action by government regulators. Employers should also be aware that the nonenforcement policy only impacts the 2024 regulations and does not eliminate the requirement to have an NQTL comparative analysis.
The information provided is a summary of laws and regulations relating to employee benefit plan compliance. This information should not be construed as legal advice. In all cases, employers should consult with their own legal counsel.
View More Insights
GLP-1s: Balancing Costs and Benefits
Obesity happens when your body stores too much fat, to the point where it can affect your health. It’s typically measured using BMI (body mass index), which is calculated by dividing your weight by the square of your height.
The Complexities Surrounding GLP-1 Agonist Drugs
The conversation around the cost and coverage of GLP-1 agonist (or GLP-1s) drugs for weight loss is one we frequently have with our clients.
Let’s make it make sense.
Pharmacy benefits clarity begins with our market analysis where we reveal data-driven insights and identify opportunities to help you make more informed decisions.